New Atrial Fibrillation Study Results Reported from Boston Health Economics (Antithrombotic use and bleeding risk in patients with atrial…
New Atrial Fibrillation Study Results Reported from Boston Health Economics (Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis)
By a
Our news journalists obtained a quote from the research from Boston Health Economics, "Outcomes were assessed over 1 year and included stroke risk (CHADS2/CHA2DS2-VASc score), bleeding risk (ATRIA score) and anticoagulant use. A total of 115,906 patients with AF met inclusion criteria between six databases. Among patients with high stroke risk (CHADS2 greater than or equal to2) and low bleeding risk (ATRIA 0-3), 42-82% did not receive an antithrombotic."
According to the news editors, the research concluded: "Levels of thromboprophylaxis for high-risk AF patients in real-world data differ significantly from current medical guidelines for stroke prevention."
For more information on this research see: Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis.
The news correspondents report that additional information may be obtained from
Keywords for this news article include: Antithrombotic, Stroke,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC
Camera captures man on hood trying to stop driver in Riverside after crash
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News